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OBJECTIVES The purpose of this study was to determine whether hyperinsulinemia during the oral glucose
tolerance test is associated with increased neointimal tissue proliferation after coronary stent
implantation in nondiabetic patients.
BACKGROUND Although hyperinsulinemia induces increased vascular smooth muscle cell proliferation in
experimental models, it has not been determined whether hyperinsulinemia is associated with
increased neointimal tissue proliferation after coronary stent implantation.
METHODS Serial (postintervention and six-month follow-up) intravascular ultrasound (IVUS) was used
to study 67 lesions treated with Palmaz-Schatz stents in 55 nondiabetic patients. Cross-
sectional images within stents were taken at every 1 mm, using an automatic pullback, and a
neointimal index was calculated as the ratio between the averaged neointimal area and
averaged stent area. All patients underwent a 75-g oral glucose tolerance test. Plasma glucose
(PG) and immunoreactive insulin (IRI) levels were measured at baseline and 1 and 2 h after
the glucose load. The sum of PGs (SPG) and the sum of IRIs (SIRI) were calculated. Body
mass index (BMI), lipid levels, and glycosylated hemoglobin levels were measured.
RESULTS There were 27 patients with normal glucose tolerance, and 28 patients with impaired glucose
tolerance (IGT). The neointimal index in patients with IGT was greater than that in patients
with normal glucose tolerance (42.9 6 14% vs. 24.9 6 8.3%, respectively, p , 0.0001). Linear
regression analysis showed that the neointimal index at follow-up correlated well with SPG
(p , 0.0001), fasting IRI (p , 0.0001), SIRI (p , 0.0001), triglyceride level (p 5 0.018),
and BMI (p , 0.0001). Multiple regression analysis revealed that SIRI (p 5 0.0002) and
SPG (p 5 0.0034) were the best predictors of the greater neointimal index at follow-up.
CONCLUSIONS Serial IVUS assessment shows that hyperinsulinemia during an oral glucose tolerance test is
associated with increased neointimal tissue proliferation after coronary stent implantation in
nondiabetic patients. (J Am Coll Cardiol 2000;36:731–8) © 2000 by the American College
of Cardiology
Although Palmaz-Schatz stent implantation has been
shown to reduce restenosis rates compared with balloon
angioplasty, in-stent restenosis remains a significant clinical
problem, especially in patients with diabetes mellitus (DM)
(1–4). Recent human histological studies demonstrated that
early thrombus formation and acute inflammation are fol-
lowed by neointimal tissue proliferation in the chronic stage
after coronary stent implantation (5,6). Using serial intra-
vascular ultrasound (IVUS) analysis, Hoffmann et al. (7)
found that stents did not recoil and that in-stent restenosis
was the result of neointimal tissue proliferation. Kornowski
et al. (8) reported that exaggerated neointimal hyperplasia in
stented lesions was the main reason for increased restenosis
in patients with DM. Increased neointimal growth after
coronary stent implantation in DM may result from mito-
gens that stimulate vascular smooth muscle cell (VSMC)
proliferation (9).
Hyperinsulinemia is attributed to insulin resistance, a
condition associated with impaired glucose tolerance (IGT)
and non-insulin-dependent DM (NIDDM). Hyperinsulin-
emia and insulin resistance have been implicated as possible
common risk factors for coronary artery disease and
NIDDM (10). It has been reported that hyperinsulinemia
induces greater VSMC proliferation in experimental models
(11,12). Hyperinsulinemia in nondiabetic patients is poten-
tially related to greater neointimal tissue proliferation, but
the relationship between hyperinsulinemia and neointimal
tissue proliferation after coronary stent implantation is
unclear. Therefore, we attempted to evaluate the relation-
ship between hyperinsulinemia and neointimal tissue pro-
liferation after coronary stent implantation in nondiabetic
patients by means of serial IVUS studies.
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METHODS
Study patients. From January 1997 through December
1997, a total of 118 patients with 144 lesions underwent
elective coronary stent implantation using Palmaz-Schatz
coronary stents (Johnson & Johnson) at Kobe General
Hospital. We studied 67 lesions from 55 nondiabetic
patients. Exclusions in this study included 1) patients with
previously treated DM (oral hypoglycemic agents or insu-
lin); 2) patients with a fasting plasma glucose level $7.0
mmol/liter (126 mg/dl); 3) patients with plasma glucose
level $11.1 mmol/liter (200 mg/dl) 2 h after 75 g oral
glucose load; 4) ostial lesions or bifurcational lesions; 5)
lesions with reference vessel diameter ,2.75 mm; 6) lesions
treated with more than two stents; and 7) lesions with
averaged stent area ,6 mm2 as measured by postinterven-
tional IVUS. There were 48 men and 7 women (mean age
60 6 7 years). Written informed consent was obtained from
each patient.
Baseline investigation. Blood pressure, body height and
body weight were measured before the angiographic proce-
dure. Body mass index (BMI) was calculated as weight (kg)
divided by height (m) squared. All patients underwent a
75-g oral glucose tolerance test (OGTT) 3 6 2 days before
coronary stent implantation. After fasting overnight, each
patient supplied blood samples at baseline and 1 and 2 h
after the glucose load. Plasma glucose levels (PG) were
measured by the enzymatic method with the use of a
Glucose Analyzer 1140 (Kyoto Daiichi Kagaku, Kyoto,
Japan), and immunoreactive insulin levels (IRI) were mea-
sured by radioimmunoassay with the use of Insulin Riabead
II (Dainabot, Tokyo, Japan). The sum of plasma glucose
(SPG 5 fasting PG 1 1 h PG 1 2 h PG) and the sum of
insulin levels (SIRI 5 fasting IRI 1 1 h IRI 1 2 h IRI)
were calculated. Glucose tolerance status was based on
World Health Organization criteria (13).
Blood chemistry analyses, including glycosylated hemo-
globin (HbA1c) levels and lipid levels, were performed at
the same time. The HbA1c was measured with the use of a
Hi-Auto A1c HA-8121 (Kyoto Daiichi Kagaku, Kyoto,
Japan). Total cholesterol and triglyceride levels were mea-
sured by the enzymatic method. High-density lipoprotein
(HDL) cholesterol levels were measured in plasma after
precipitation of low-density lipoprotein (LDL) and very-
low-density lipoprotein. The LDL cholesterol concentra-
tions were calculated using the following formula: LDL
cholesterol 5 total cholesterol 2HDL cholesterol 2(tri-
glyceride/5) (14).
Implantation of Palmaz-Schatz stent. Palmaz-Schatz
stents were implanted according to standard protocols. The
IVUS was used to guide high-pressure adjunctive balloon
inflation to achieve targeted stent expansion. The targeted
stent expansion was a minimal stent area of $80% of the
average of the proximal and distal reference lumen cross-
sectional areas by IVUS as well as complete stent–vessel wall
apposition. All patients received 160 mg of aspirin and
200 mg of ticlopidine. The duration of ticlopidine treatment
was four weeks.
Serial intravascular ultrasound imaging. The IVUS im-
agings were performed at postintervention (after the final
balloon inflation) and at follow-up (6.3 6 0.6 months after
the stent implantation). After administration of 1 to 2 mg of
intracoronary isosorbide dinitrate, a 30-MHz, 3.2F IVUS
catheter (Cardiovascular Imaging System, Sunnyvale, Cal-
ifornia) was advanced to the distal site in the coronary artery
beyond the target lesion. Continuous images of the coronary
artery from beyond the target lesion to the aorto-ostial
junction were obtained as the ultrasound catheter was slowly
withdrawn at 0.5 mm/s using a motorized pullback device.
The IVUS images were recorded on a 0.5-in. sVHS video
tape for offline analysis. The IVUS examinations were
considered suitable for analysis if images were free from
apparent ultrasound artifacts such as oblique catheter posi-
tioning or nonuniform rotational distortion.
Quantitative IVUS measurements. With the use of
computer-assisted planimetry (Tape-Measure, Indec Sys-
tem, Capitola, California), quantitative IVUS measure-
ments were performed by a single individual who was
blinded to the results of OGTT. The IVUS recordings after
stent implantation and at follow-up were replayed on a
video screen, and cross-sectional images within stents were
selected at every 1 mm (given a pull-back speed of 0.5
mm/s, each 2 s of video playback corresponds to 1 mm of
axial length). Fourteen to 16 image slices were selected from
each stent. After digitizing individual image slices, the stent
cross-sectional and lumen cross-sectional areas were mea-
sured, and the neointimal area was calculated as the differ-
ence between the stent area and lumen area (Fig. 1). In cases
with in-stent restenosis at follow-up, IVUS imagings were
performed before the interventional procedure. When the
tissue encompassed the catheter, the lumen was assumed to
be the physical size of the imaging catheter. Therefore,
1.0 mm was the smallest minimal lumen diameter (MLD),
and 0.8 mm2 was the smallest lumen cross-sectional area
that could be measured before intervention (15). Because it
was difficult to measure the stent area accurately in the
image slice at the central articulation, the image slice at this
point was excluded from the analysis. All measurements
Abbreviations and Acronyms
BMI 5 body mass index
DM 5 diabetes mellitus
HbA1c 5 glycosylated hemoglobin level
IGT 5 impaired glucose tolerance
IRI 5 immunoreactive insulin level
IVUS 5 intravascular ultrasound
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MLD 5 minimal lumen diameter
NIDDM 5 non-insulin-dependent diabetes mellitus
OGTT 5 oral glucose tolerance test
PG 5 plasma glucose level
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were averaged over the number of selected slices. The
neointimal index was calculated as the ratio between aver-
aged neointimal area and averaged stent area. Reproducibil-
ity of the IVUS measurements has been previously reported
(16).
Quantitative angiographic analysis. Quantitative coro-
nary angiography was performed using an automated edge
detection system CMS (Medis Medical Imaging Systems,
Leiden, the Netherlands) by a single individual who was
blinded to the OGTT results. A contrast-filled, nontapered
catheter tip was used for calibration. The MLD, reference
diameter, percent diameter stenosis, and the diameter of the
maximally inflated balloon were measured. Measurements
were taken from multiple projections, and the results from
the “worst” views were recorded. A balloon-vessel ratio was
calculated by dividing the diameter of an inflated balloon by
the coronary reference diameter. Stents were considered
restenotic if the quantitative angiographic diameter stenosis
at follow-up was $50%.
Statistical analysis. Quantitative data are presented as
mean 6 SD. Differences in categorical variables were
analyzed by the Fisher exact probability test, and differences
in continuous variables were compared between the two
groups using the Mann-Whitney U-test. Results of IVUS
measurements and clinical, angiographic, and procedural
characteristics were determined using a lesion-based assess-
ment. Previous studies have shown that stented lesions
behave independently with regard to restenosis when mul-
tiple lesions are treated in the same patients (17). A
two-side value of p , 0.05 was considered statistically
significant. Multivariate linear regression analysis was used
to determine the best predictors of the neointimal index at
follow-up. Univariate predictors of the neointimal index at
follow-up with a p value , 0.20 were entered into the
multivariate model. The best independent predictors and
their correlation coefficients were calculated.
Table 1. Baseline Characteristics, Results of Oral Glucose Tolerance Test and Lipid Analysis
Normal Glucose
Tolerance
(n 5 34 stents)
IGT




Gender (male/female) 28/6 31/2 0.2585
Age 60 6 9 59 6 6 0.7161
Systolic blood pressure (mm Hg) 130 6 22 130 6 18 0.9900
Diastolic blood pressure (mm Hg) 67 6 9 69 6 12 0.6248
Body mass index (kg/m2) 22.5 6 2.2 24.8 6 2.7 0.0006
Prior myocardial infarction 16 (47%) 18 (55%) 0.6278
Coronary risk factors
Hypertension 18 (53%) 13 (39%) 0.3802
Hyperlipidemia 23 (68%) 26 (79%) 0.4101
Current smoking 12 (35%) 10 (30%) .0.9999
Familial history 6 (18%) 7 (21%) 0.7652
Fasting plasma glucose (mmol/liter) 5.31 6 0.47 5.37 6 0.60 0.7874
1-h plasma glucose (mmol/liter) 9.42 6 1.64 11.22 6 1.51 0.0001
2-h plasma glucose (mmol/liter) 6.53 6 0.86 8.93 6 0.95 ,0.0001
S Plasma glucose (mmol/liter) 21.27 6 2.38 25.32 6 2.31 ,0.0001
Fasting insulin (mU/ml) 4.7 6 1.5 7.7 6 2.7 ,0.0001
1-h insulin (mU/ml) 63.2 6 45.6 99.9 6 64.3 0.0071
2-h insulin (mU/ml) 44.1 6 25.7 98.3 6 78.8 ,0.0001
S Insulin (mU/ml) 111.9 6 55.9 206.0 6 135.3 0.0002
Glycosylated hemoglobin A1c (%) 5.3 6 0.3 5.2 6 0.3 0.8508
Total cholesterol (mmol/liter) 5.01 6 0.65 5.19 6 0.64 0.8214
Triglyceride (mmol/liter) 1.41 6 0.60 1.63 6 0.64 0.0700
HDL Cholesterol (mmol/liter) 1.07 6 0.20 1.06 6 0.25 0.8214
LDL Cholesterol (mmol/liter) 3.30 6 0.54 3.39 6 0.56 .0.9999
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
Figure 1. Representative planar intravascular ultrasound images of Palmaz-
Schatz stent at follow-up are shown. Each is duplicated, and the duplicate
is labeled. In patient without glucose intolerance (left), the stent area
measured 6.4 mm2, and the lumen area measured 4.6 mm2. Thus, there
was 1.8 mm2 of neointimal tissue proliferation and the neointimal index
was 28%. In patient with impaired glucose tolerance (right), the stent area
measured 6.3 mm2, and the lumen area measured 2.2 mm2. Thus, there
was 4.1 mm2 of neointimal tissue proliferation and the neointimal index
was 65%.
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RESULTS
All patients underwent follow-up angiography as part of the
study protocol. Nine of the patients had recurrent symptoms
at the time of follow-up, but no patients presented with
unstable angina or myocardial infarction.
Baseline characteristics, the results of OGTT, and blood
chemistry analyses are shown in Table 1. Twenty-seven
patients with 34 stents had normal glucose tolerance, and 28
patients with 33 stents had abnormal glucose tolerance. The
BMI in patients with IGT was significantly greater than
that in patients with normal glucose tolerance. There was no
difference between the two groups in the incidence of other
coronary risk factors. There was no patient with renal
dysfunction in this study. Although no difference was seen
in fasting PG between the two groups, 1- and 2-h PG and
SPG in the IGT group were significantly greater than those
in the normal glucose tolerance group. Fasting IRI, 1-h IRI,
2-h IRI, and SIRI were significantly greater in patients with
IGT than in patients with normal glucose tolerance. No
differences existed in lipid levels and HbA1c levels between
the two groups.
Angiographic and procedural characteristics are shown in
Table 2. No differences were seen between the two groups
in target vessel, lesion location, or modified ACC/AHA
lesion classifications (18). No differences occurred in prein-
terventional reference vessel diameters, MLD, or lesion
lengths between the two groups. There were no differences
in final balloon diameters, balloon-to-artery ratio, or final
balloon inflation pressure between the two groups. Postpro-
cedural residual dissections were present in two cases (6%)
in the normal glucose tolerance group versus one case (3%)
in the IGT group (p . 0.9999). Neither slow flow nor
thrombus formation occurred after stent implantation in
this study. There were 14 stents with restenosis identified by
follow-up angiography: 4 (13%) of the 34 stents in the
normal glucose tolerance group and 10 (30%) of the 33
stents in the IGT group (p 5 0.0772). Focal in-stent
restenosis was present in two cases in the normal glucose
tolerance group versus one in the IGT group, and diffuse
in-stent restenosis was present in two cases in the normal
glucose tolerance group versus nine in the IGT group (p 5
0.1758).
Results of serial IVUS measurements are shown in Table
3. No significant differences in stent area were seen between
the two groups at postintervention or at six months’ follow-
up. However, the lumen area at follow-up in the IGT group
was significantly smaller than that in the normal glucose
tolerance group. This was also true for the minimal lumen
area (MLA) within stent. The neointimal area and neoin-
timal index at follow-up in the IGT group were significantly
greater than those in the normal glucose tolerance group.
This was also true for the neointimal area and neointimal
index in the image slices with MLA.
Results of univariate linear regression analysis are shown
in Table 4 and Figure 2. Greater BMI, SPG, fasting IRI,
SIRI, and triglyceride values were all associated with a
greater neointimal index at follow-up. However, the neoin-
timal index was not associated with the HbA1c level, the
cholesterol levels, or any of the angiographic or procedural
factors. As shown in Table 5, multiple linear regression
Table 2. Angiographic and Procedural Characteristics
Normal Glucose
Tolerance
(n 5 34 stents)
IGT





Left anterior descending artery 24 (71%) 19 (58%) 0.3145
Left circumflex artery 1 (3%) 3 (9%) 0.3559
Right coronary artery 9 (26%) 11 (33%) 0.6002
Left main coronary artery 0 (0%) 0 (0%) .0.9999
Saphenous vein graft 0 (0%) 0 (0%) .0.9999
Target lesion location
Proximal 14 (41%) 14 (42%) .0.9999
Mid 20 (59%) 19 (58%) .0.9999
Distal 0 (0%) 0 (0%) .0.9999
Modified AHA/ACC lesion classification
A 3 (9%) 2 (6%) .0.9999
B1 10 (29%) 13 (39%) 0.4469
B2 20 (59%) 17 (52%) 0.6267
C 1 (3%) 1 (3%) .0.9999
Restenotic lesion 11 (32%) 11 (33%) .0.9999
Chronic occlusion 1 (3%) 1 (3%) .0.9999
Pre-reference diameter (mm) 3.1 6 0.3 3.2 6 0.3 0.1736
Pre-minimal lumen diameter (mm) 0.9 6 0.2 0.9 6 0.2 0.1389
Pre-diameter stenosis (%) 71 6 7 71 6 5 0.5683
Pre-lesion length (mm) 10.5 6 2.6 10.9 6 1.9 0.4150
Balloon diameter (mm) 3.4 6 0.3 3.4 6 0.3 0.6974
Balloon artery ratio 1.1 6 0.1 1.1 6 0.1 0.0749
Balloon inflation pressure (atm) 15.2 6 1.5 14.6 6 1.7 0.2167
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analysis revealed that SIRI and SPG were significant
predictors of the greater neointimal index at follow-up.
DISCUSSION
Using serial IVUS analysis, the present study on nondiabetic
patients demonstrated that 1) greater neointimal tissue
proliferation occurred in patients with IGT defined by
OGTT than in patients with normal glucose tolerance, and
2) SIRI and SPG after the glucose load were significant
predictors of the greater neointimal growth at six months’
follow-up after coronary stent implantation.
Previous studies. Several studies using B-mode ultrasound
in humans reported that hyperinsulinemia is associated with
greater intimal medial thickening of the carotid artery
(19,20). After vascular injury, including coronary interven-
tion, hyperinsulinemia is potentially associated with greater
neointimal tissue proliferation. However, no previous re-
ports evaluated the relationship between hyperinsulinemia
and neointimal tissue proliferation following coronary stent
implantation. A recent angiographic analysis reported that
hyperinsulinemia after the glucose load is associated with
greater late lumen loss after balloon angioplasty (21,22).
Several IVUS studies have indicated that late lumen loss
after intervention in nonstented lesions is primarily deter-
mined not by cellular proliferation, but by the direction and
magnitude of arterial remodeling (23,24). Meanwhile,
IVUS study has demonstrated that chronic stent recoil is
minimal and that the late lumen loss and in-stent restenosis




Coefficient t Value p Value
Clinical characteristics
Age 0.094 0.242 0.391 0.6974
Systolic blood pressure 20.068 0.088 20.773 0.4425
Diastolic blood pressure 20.054 0.175 20.306 0.7603
Body mass index 2.353 0.601 3.916 0.0002
OGTT and lipid analysis
Fasting plasma glucose 1.412 3.386 0.417 0.6780
S Plasma glucose 2.453 0.496 4.949 ,0.0001
Fasting insulin 2.919 0.583 5.011 ,0.0001
S insulin 0.080 0.013 6.370 ,0.0001
HbA1c 4.784 6.215 0.770 0.4443
Total cholesterol 1.300 2.771 0.469 0.6406
Triglyceride 6.687 2.76 2.423 0.0182
HDL cholesterol 1.580 0.025 0.198 0.8433
LDL cholesterol 22.178 3.289 20.662 0.5102
Angiographic and procedural
characteristics
Reference diameter 2.279 5.293 0.431 0.6682
Minimal lumen diameter 8.539 9.384 0.910 0.3662
% Diameter stenosis 20.193 0.297 20.651 0.5173
Lesion length 1.055 0.785 1.343 0.1839
Balloon diameter 0.486 5.874 0.083 0.9344
Balloon artery ratio 215.886 28.639 20.555 0.5810
Balloon inflation pressure 0.111 1.121 0.099 0.9211
Postinterventional IVUS variable
Stent area 0.382 0.967 0.395 0.4465
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
Table 3. Results of Serial Intravascular Ultrasound Analysis
Normal Glucose
Tolerance
(n 5 34 stents)
IGT




Follow-up interval (months) 6.4 6 0.6 6.2 6 0.6 0.3800
Post-stent area (mm2) 8.1 6 1.7 8.5 6 2.0 0.4008
F/U stent area (mm2) 8.1 6 1.6 8.4 6 2.1 0.6071
F/U lumen area (mm2) 6.1 6 1.5 4.8 6 1.7 0.0006
F/U neointimal area (mm2) 2.0 6 0.7 3.6 6 1.9 ,0.0001
F/U neointimal index (%) 24.9 6 8.3 42.9 6 14.0 ,0.0001
F/U stent area (mm2) at MLA 7.5 6 1.6 7.8 6 2.0 0.6653
F/U minimal lumen area (mm2) 4.8 6 1.6 3.7 6 1.9 0.0078
F/U neointimal area (mm2) at MLA 2.6 6 1.5 4.0 6 2.2 0.0015
F/U neointimal index (%) at MLA 35.1 6 17.8 50.5 6 19.9 0.0014
Post 5 postinterventional; F/U 5 follow-up; MLA 5 minimal lumen area.
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are the results of neointimal tissue proliferation (7).
Komatsu et al. (5) and Farb et al. (6) have demonstrated that
in long-term stents (.30 days after stent implantation) the
histological success or failure was determined by degree of
neointimal growth within the stents. Therefore, the present
study is the first to demonstrate that hyperinsulinemia is
associated with an increase in neointimal tissue proliferation
that may contribute to restenosis after coronary interven-
tion.
Hyperinsulinemia and insulin resistance. Although we
found a strong relationship between hyperinsulinemia and
neointimal tissue proliferation after coronary stent implan-
tation, further investigation is necessary to determine
whether hyperinsulinemia itself induces greater neointimal
tissue proliferation. Physiological concentrations of insulin
are known to stimulate proliferation of cultured VSMC and
fibroblasts (10,11). Though insulin itself is a weak mitogen,
it can potentiate the expression of the more potent mitogens
(such as platelet-derived growth factor and insulin-like
growth factor) (25,26). In addition, in vivo studies have
demonstrated that an intra-arterial injection of insulin
induces atheroma growth in the injected artery (27,28).
These findings suggest that insulin has an atherogenic
action.
However, according to a recent review of 25 prospective
studies correlating insulin levels with heart disease, epide-
miological evidence does not support the notion that hy-
perinsulinemia is a major risk factor for heart disease (29).
The available evidence suggests that it is insulin resistance,
per se, and not hyperinsulinemia, that is associated with
atherosclerosis, thrombogenesis, hypertension, obesity, and
DM (30). A recent investigation using B-mode ultrasound
reported that the intimal medial thickness of the carotid
artery is related to reduced insulin sensitivity but not to
insulin levels (31). It is plausible that the relationship
between hyperinsulinemia and increased neointimal tissue
proliferation is not associated with the atherogenic action of
insulin, but is based on the association between insulin
resistance and atherosclerosis (32). In this study, we did not
measure insulin resistance directly. Although hyperinsulin-
emia often indicates insulin resistance, the two are not
necessarily identical. Further study is necessary to evaluate
the relationship between insulin resistance directly assessed
by the intravenous glucose tolerance test and neointimal
tissue proliferation after coronary stent implantation. How-
ever, previous reports cannot rule out the possibility that the
compensatory hyperinsulinemia directly related to insulin
resistance plays a direct or indirect role in the pathogenesis
of atherosclerosis (33).
As shown in Table 5, multiple regression analysis re-
vealed that SPG was also a significant predictor of neoin-
timal index at follow-up. Because hyperinsulinemia and
hyperglycemia link together in patients with IGT, it is
difficult to eliminate the effects of hyperglycemia as an
important promoter of increased neointimal tissue prolifer-
ation after coronary stent implantation. Hyperglycemia can
promote neointimal tissue proliferation not only through
compensatory hyperinsulinemia, but also through its effects
on endothelial dysfunction, dysregulation of growth factor
expression, advanced glycosylation end products, and abnor-
mal extracellular matrix composition (9).
Study limitations. The present study has some intrinsic
limitations. The first is that it is a single center study with
Figure 2. Relation between insulin levels (top panel) and plasma glucose
levels (bottom panel) and neointimal index.










Intercept 234.382 14.861 264.109–4.655
Body mass index 0.714 0.589 20.464–1.892 1.213 0.2299
S Plasma glucose 1.502 0.492 0.518–2.486 3.053 0.0034
Fasting insulin 20.239 0.776 21.790–1.313 20.308 0.7591
S Insulin 0.060 0.015 0.029–0.091 3.927 0.0002
Triglyceride 2.139 2.145 22.152–6.430 0.997 0.3228
Lesion length 0.479 0.582 20.685–1.643 0.823 0.4139
Multiple R 5 0.73, R2 5 0.53.
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a relatively small number of study patients. Second, we
excluded patients with DM. Insulin response to a glucose
load may be different in patients with DM because of their
insulin secretory defect. Moreover, in patients who receive
administration of insulin, the effect of exogenous insulin on
neointimal tissue proliferation is unclear. Further study in
patients with DM is required to evaluate the relationship
between hyperinsulinemia and/or insulin resistance and
increased neointimal tissue proliferation after coronary stent
implantation.
The third limitation is our exclusion of lesions with small
reference vessel diameters or small stent areas. Previous
studies have reported that the reference vessel diameter and
final stent dimensions (either MLD or stent area) were
significant predictors of angiographic MLD at six months’
follow-up. A recent study (34) using IVUS has shown that
intimal hyperplasia thickness at follow-up is independent of
the stent size. If neointimal thickness is a relative constant
and is independent of stent size, then there must be a
greater encroachment on the lumen dimensions of smaller
stents implanted into smaller vessels. Therefore, the effect of
hyperinsulinemia on promoting neointimal tissue prolifera-
tion may be much more important in smaller stents than in
larger ones.
A fourth limitation in this study is that IVUS images at
the central articulation were excluded from the analysis.
Several angiographic studies and IVUS studies have pointed
out that the central articulation is the most frequent site for
restenosis in Palmaz-Schatz stents (35,36). However, a
recent study (7) using serial IVUS showed that the tendency
for increased neointimal tissue accumulation at the central
articulation was modest in comparison to the otherwise
uniform neointimal tissue accumulation over the length of
the stent.
Finally, we used the neointimal index to estimate neoin-
timal tissue accumulation over the stent lengths. Using this
index, we could underestimate the focal high-grade in-stent
restenosis where the neointimal accumulation is localized.
However, aggressive neointimal growth in the diffuse in-
stent restenosis, a condition indicated in this study by a
greater neointimal index, has been more often associated
with a higher frequency of recurrent restenosis after the
angioplasty than with focal in-stent restenosis.
Clinical implications. Treatment strategies designed to
limit cellular proliferation may be efficacious in reducing
in-stent restenosis. An animal experimental study has
shown that pharmacological therapy following coronary
stent implantation reduces in-stent restenosis by inhibiting
neointimal hyperplasia (37). Several studies have shown that
stent implantation combined with radiation vascular therapy
reduces in-stent restenosis (38,39). Although patients who
experience hyperinsulinemia and/or hyperglycemia after a
glucose load do not have clinically significant DM, the
present study suggests that they are good candidates for
these adjunct therapies following coronary stent implanta-
tion to reduce in-stent restenosis.
Conclusions. Serial IVUS assessment reveals that hyper-
insulinemia and hyperglycemia after a glucose load are
associated with greater neointimal tissue proliferation after
coronary stent implantation in nondiabetic patients.
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